Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCABNASDAQ:EVOKNASDAQ:MENASDAQ:MIRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCABBioAtla$0.40+0.7%$0.42$0.24▼$2.53$23.45M0.92939,508 shs632,873 shsEVOKEvoke Pharma$2.69-1.6%$2.99$1.94▼$12.32$4.00M0.04124,848 shs3,515 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.42 million shs29.28 million shsMIRAMIRA Pharmaceuticals$1.22-0.8%$1.20$0.51▼$5.01$20.64M1.962.20 million shs84,335 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCABBioAtla0.00%-1.01%+2.92%+8.49%-73.42%EVOKEvoke Pharma0.00%-7.09%-26.56%-4.45%-63.32%ME23andMe0.00%0.00%0.00%-31.78%-94.12%MIRAMIRA Pharmaceuticals0.00%+0.83%0.00%-0.81%+70.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCABBioAtla2.6354 of 5 stars3.32.00.00.03.22.50.6EVOKEvoke Pharma0.4378 of 5 stars0.05.00.00.00.00.00.6ME23andMeN/AN/AN/AN/AN/AN/AN/AN/AMIRAMIRA Pharmaceuticals2.3821 of 5 stars3.75.00.00.00.60.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCABBioAtla 2.50Moderate Buy$5.001,145.64% UpsideEVOKEvoke Pharma 0.00N/AN/AN/AME23andMe 1.00SellN/AN/AMIRAMIRA Pharmaceuticals 3.33Buy$14.001,047.54% UpsideCurrent Analyst Ratings BreakdownLatest EVOK, BCAB, MIRA, and ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025BCABBioAtlaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCABBioAtla$11M2.13N/AN/A$0.25 per share1.61EVOKEvoke Pharma$10.25M0.39N/AN/A$4.74 per share0.57ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21MIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)EVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/AMIRAMIRA Pharmaceuticals-$7.85M-$0.51N/AN/AN/AN/A-341.08%-272.93%8/12/2025 (Estimated)Latest EVOK, BCAB, MIRA, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MIRAMIRA Pharmaceuticals-$0.15-$0.11+$0.04-$0.11N/AN/A5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/A3/28/2025Q4 2024MIRAMIRA Pharmaceuticals-$0.29-$0.15+$0.14-$0.15N/AN/A3/27/2025Q4 2024BCABBioAtla-$0.40-$0.32+$0.08-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCABBioAtlaN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCABBioAtlaN/A2.352.35EVOKEvoke PharmaN/A1.551.50ME23andMeN/A1.050.91MIRAMIRA PharmaceuticalsN/A12.8612.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCABBioAtla77.23%EVOKEvoke PharmaN/AME23andMe36.10%MIRAMIRA Pharmaceuticals35.16%Insider OwnershipCompanyInsider OwnershipBCABBioAtla11.50%EVOKEvoke Pharma6.10%ME23andMe26.32%MIRAMIRA Pharmaceuticals6.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCABBioAtla6058.42 million51.70 millionOptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableMIRAMIRA Pharmaceuticals216.92 million15.80 millionNot OptionableEVOK, BCAB, MIRA, and ME HeadlinesRecent News About These CompaniesMIRA Gets Validation from JournalJune 18, 2025 | finance.yahoo.comMIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in PharmacologyJune 18, 2025 | accessnewswire.comMIRA Pharmaceuticals’ Ketamir-2 Published in Pharmacology JournalJune 17, 2025 | tipranks.comVisionstate Launches MIRA to Digitize Facility Inspections and Expand SaaS PlatformJune 5, 2025 | thenewswire.comMIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical ProgramMay 28, 2025 | accessnewswire.comMIRA Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comMIRA Releases Financials as Research ContinuesMay 15, 2025 | finance.yahoo.comMIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60MMay 9, 2025 | msn.comMIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment StrongMay 9, 2025 | msn.comMIRA Pharmaceuticals Acquires SKNY Pharmaceuticals for $60MMay 8, 2025 | tipranks.comMIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent ReviewMay 8, 2025 | accessnewswire.comMIRA Sets Up Success With Stellar Safety ResultsMay 7, 2025 | msn.comMIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked NeurotoxicityMay 6, 2025 | accessnewswire.comMira Pharmaceuticals reports in vitro drug release data for topical Ketamir-2April 25, 2025 | markets.businessinsider.comMIRA Pain Treatment Expands Market Size PotentialApril 23, 2025 | msn.comMIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track DesignationApril 23, 2025 | accessnewswire.comPharmaceutical Stock Jumps After Key Trial FindingsApril 17, 2025 | msn.comMira Pharmaceuticals announces results for Ketamir-2 in diabetic neuropathyApril 17, 2025 | markets.businessinsider.comMira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical TrialApril 17, 2025 | msn.comMIRA Continues Positive Testing RunApril 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeQuantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationBy Leo Miller | May 27, 2025View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA DeclarationTop 5 Stock Buys for June: AI Picks That Aren’t NVIDIABy Thomas Hughes | May 29, 2025View Top 5 Stock Buys for June: AI Picks That Aren’t NVIDIAConstellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawEVOK, BCAB, MIRA, and ME Company DescriptionsBioAtla NASDAQ:BCAB$0.40 +0.00 (+0.73%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.42 +0.02 (+4.38%) As of 06/20/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Evoke Pharma NASDAQ:EVOK$2.68 -0.05 (-1.65%) Closing price 06/20/2025 03:20 PM EasternExtended Trading$2.68 0.00 (0.00%) As of 06/20/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.MIRA Pharmaceuticals NASDAQ:MIRA$1.22 -0.01 (-0.81%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.22 0.00 (-0.41%) As of 06/20/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
